Skip to main navigation

Main Menu

About
Our Approach
Pipeline
- Publications
Therapeutic Focus
Join Our Team
- Current Openings
- Faces of Fulcrum
Investor Relations
Contact

News Releases

News Releases

Year

Jun 24, 2020

Fulcrum Therapeutics Announces Initiation of Multi-Center Phase 3 (LOSVID) Trial with Losmapimod for Hospitalized COVID-19 Patients

Jun 10, 2020

Fulcrum Therapeutics Completes $68.5 Million Private Placement

Jun 10, 2020

Fulcrum Therapeutics to Evaluate Losmapimod as Potential Treatment for COVID-19

May 21, 2020

Fulcrum Therapeutics Announces Multiple Presentations at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform

May 13, 2020

Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results

May 11, 2020

Fulcrum Therapeutics to Present at the BofA Securities 2020 Health Care Conference

May 07, 2020

Fulcrum Therapeutics to Host First Quarter 2020 Financial Results Conference Call and Webcast on Wednesday, May 13, 2020 at 8:00 a.m. ET

Apr 13, 2020

Fulcrum Therapeutics Announces Completion of IND-enabling Safety Studies for FTX-6058 in Sickle Cell Disease

Apr 02, 2020

Fulcrum Therapeutics Provides Business Update on Impact of COVID-19

Mar 24, 2020

Fulcrum Therapeutics Announces Complete Data from Phase 1 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 17

Investor Tools

Privacy Policy
EU Privacy Policy
Terms of Use

Twitter
LinkedIn
Instagram

Main Menu

About
Our Approach
Pipeline
- Publications
Therapeutic Focus
Join Our Team
- Current Openings
- Faces of Fulcrum
Investor Relations
Contact